



eTheRNA immunotherapies NV is developing an mRNA immunotherapy for the treatment of melanoma.

1) Concept

- The 5-year survival rate of late-stage melanoma is merely 27%. Based on eTheRNA's immune-boosting TriMix technology, eTheRNA offers a very well tolerated and efficacious immunotherapy to treat melanoma and **prevent relapse**.
- Product: autologous dendritic cells electroporated ex vivo with **TriMix** and **tumour-associated antigen mRNA**



2) Clinical

- Clinical evidence from **2 Phase I** safety studies in unresectable melanoma and adjuvant melanoma
- **2 Phase II** POC studies in unresectable melanoma and adjuvant melanoma

3) Efficacy

- 7/39 end-stage melanoma patients cured in combination with ipilimumab
- **65% of melanoma patients** in adjuvant setting disease free at 1 year, vs 34% in the control arm



4) Next Steps

- Pivotal phase II/III study in unresectable melanoma and/or adjuvant setting
- Development of **off-the-shelf product**: naked TriMix and tumour-associated antigen mRNA **injected intranodally**
 - Phase Ib/IIa data demonstrate safety and immunogenicity